CG Oncology Valuation Multiples

CG Oncology Overview

About CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Founded

2010

HQ

Employees

113

Website

cgoncology.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $7M

EBITDA: ($203M)

EV

$5B

Valuation Multiples

Multiples.vc

Start free trial

CG Oncology Financials

CG Oncology reported last 12-month revenue of $7M and negative EBITDA of ($203M).

In the same LTM period, CG Oncology generated $3M in gross profit, ($203M) in EBITDA losses, and had net loss of ($173M).

CG Oncology P&L

In the most recent fiscal year, CG Oncology reported revenue of $4M and EBITDA of ($189M).

CG Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX

CG Oncology Stock Performance

CG Oncology has current market cap of $6B, and enterprise value of $5B.

CG Oncology's stock price is $68.57.

CG Oncology Valuation Multiples

CG Oncology trades at 737.4x EV/Revenue multiple, and (24.9x) EV/EBITDA.

CG Oncology Financial Valuation Multiples

As of April 11, 2026, CG Oncology has market cap of $6B and EV of $5B.

Equity research analysts estimate CG Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CG Oncology has a P/E ratio of (33.5x).

CG Oncology Margins & Growth Rates

CG Oncology's revenue in the last 12 month grew by 615%.

CG Oncology's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.7M for the same period.

CG Oncology's rule of 40 is (1410%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CG Oncology's rule of X is (1029%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

CG Oncology Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

CG Oncology M&A Activity

CG Oncology acquired XXX companies to date.

Last acquisition by CG Oncology was on XXXXXXXX, XXXXX. CG Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

CG Oncology Investment Activity

CG Oncology invested in XXX companies to date.

CG Oncology made its latest investment on XXXXXXXX, XXXXX. CG Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).